Abstract: The present invention describes a method for determining whether an individual is likely to suffer from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.
Type:
Grant
Filed:
June 9, 2006
Date of Patent:
October 5, 2010
Assignee:
Rigshospitalet
Inventors:
Mads Holten-Andersen, Ross Stephens, Hans Jørgen Nielsen, Ib Jarle Christensen, Nils Brünner
Abstract: The invention provides a method for suppressing tumor cell growth in a patient, comprising: administering to the patient an effective amount of an expression vector including a polynucleotide encoding a tumor suppressor protein having SEQ ID NO: 1 under conditions wherein the expression vector incorporates itself into the tumor cell genome and inhibits cell proliferation or induces cell death. The invention further provides a method for a method for inhibiting tumor cell proliferation in a tumor cell population comprising: administering to the tumor cell population an amount of a composition comprising a tumor suppressor protein having SEQ ID NO: 1 effective to inhibit tumor cell proliferation therein.
Abstract: A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.
Abstract: The present invention concerns immunoglobulins, particularly antibodies which specifically bind human Interleukin 13 (hIL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hIL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Pharmaceutical compositions comprising said antibodies and methods of manufacture are also disclosed.
Type:
Grant
Filed:
June 30, 2005
Date of Patent:
October 5, 2010
Assignee:
Glaxo Group Limited
Inventors:
Claire Ashman, Martin John Cassidy, Jonathan Henry Ellis, Trevor Anthony Kenneth Wattam
Abstract: The present invention provides novel androgen regulated nucleic acid molecules. Related polypeptides and diagnostic methods also are provided.
Abstract: Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and reduced metastasis using mutant LIGHT are disclosed.
Abstract: A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen.
Type:
Grant
Filed:
February 5, 2009
Date of Patent:
October 5, 2010
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal cancers, autoimmune diseases, and related conditions.
Type:
Grant
Filed:
December 13, 2005
Date of Patent:
September 28, 2010
Assignee:
GlaxoSmithKline Biologicals S.A.
Inventors:
Teresa Elisa Virginia Cabezon-Silva, Jean-Pol Cassart, Thierry Coche, Swann Romain Jean-Thomas Gaulis, Carlota Vinals Y De Bassols
Abstract: A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.
Type:
Grant
Filed:
September 16, 2008
Date of Patent:
September 28, 2010
Assignee:
Agensys Inc.
Inventors:
Daniel E. Afar, Rene S. Hubert, Stephen Chappell Mitchell
Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.
Type:
Grant
Filed:
October 7, 2004
Date of Patent:
September 21, 2010
Assignees:
Millennium Pharmaceuticals, Inc., Board of Regents, University of Texas System
Inventors:
Wilson O. Endege, Donna Ford, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, John E. Monahan, Robert Schlegel, Yong Yao Xu, Xumei Zhao
Abstract: The present invention provides for a proteomic approach to grading gliomas, and for predicting patient survival. In addition to employing global protein expression patterns, such as by mass spectrometry, particular target proteins whose expression is altered in various gliomas can be used to predict the stage/classification of a glioma, as well as to indicate whether a given patient will be a short- or long-term survivor.
Abstract: The invention provides methods for inhibiting tumor cell proliferation by inhibiting FoxM1B activity, expression, or nuclear localization in a tumor cell. The invention also provides methods for preventing tumor progression in an animal comprising inhibiting FoxM1B activity, expression, or nuclear localization. Furthermore, the invention provides methods for inhibiting tumor cell growth in an animal comprising inhibiting FoxM1B activity, expression, or nuclear localization in tumor cells in the animal.
Type:
Grant
Filed:
June 10, 2005
Date of Patent:
September 21, 2010
Assignee:
The Board of Trustees of the University of Illinois
Inventors:
Robert Costa, Pradip Raychaudhuri, Xinhe Wang, Vladimir Kalinichenko, Michael Major, I-Ching Wang
Abstract: The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein.
Type:
Grant
Filed:
April 16, 2004
Date of Patent:
September 21, 2010
Assignee:
Genentech, Inc.
Inventors:
Heidi Ackerly, Avi Ashkenazi, David Eberhard, Gretchen Frantz, Dorothy French, Germaine G. Fuh, Jo-Anne S. Hongo, Chingwei V. Lee, Scot A. Masters, Helga A. Raab, Evgeny Varfolomeev, Beni B. Wolf, Robert Maurice Pitti, Liliana Soroceanu
Abstract: The present invention relates to a novel agent for treating chondroma and chondrosarcoma containing a substance which inhibits binding of parathyroid hormone related peptide to its receptor for improving the prognosis of chondroma or chondrosarcoma.
Abstract: Methods and materials for inducing anti-tumor responses in melanoma patients are disclosed. These methods and materials involve gp100-derived polypeptides that contain both a helper T-cell epitope and a cytotoxic T-cell epitope.
Type:
Grant
Filed:
January 22, 2008
Date of Patent:
September 14, 2010
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: The invention provides methods of detecting West Nile virus and oligonucleotide reagents derived from a West Nile virus consensus sequence that are useful in the methods of the invention.
Type:
Grant
Filed:
November 6, 2007
Date of Patent:
September 14, 2010
Assignee:
Bayer HealthCare LLC
Inventors:
Stefan H. M. Burde, Todd M. Gierman, Christopher C. Glenn
Abstract: The present invention relates generally to methods of inhibiting angiogenesis in a patient by administering an effective angiogenesis-inhibiting amount of a thrombin inhibitor, and to the treatment of disease states that result from uncontrolled cell proliferation by administering a thrombin inhibitor alone or co-administering a thrombin inhibitor with an anticancer or cytotoxic agent. Specifically, the thrombin inhibitors used in the methods of the present invention are hirudins.
Abstract: Monotherapies and combination therapies for treating hyperproliferative disorders are described, as are compositions for performing such methods.
Type:
Grant
Filed:
October 28, 2005
Date of Patent:
September 14, 2010
Assignee:
Lpath, Inc.
Inventors:
Roger A. Sabbadini, Amy L. Cavalli, William A. Garland
Abstract: A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.
Type:
Grant
Filed:
May 21, 2007
Date of Patent:
September 14, 2010
Assignee:
Agensys, Inc.
Inventors:
Aya Jakobovits, Arthur B. Raitano, Daniel E. H. Afar, Douglas Saffran, Rene S. Hubert, Mary Faris, Pia M. Challita-Eid
Abstract: The invention provides the identification and characterization of disease and cancer-associated epitope, KID3. The invention also provides a family of monoclonal antibodies that bind to KID3, methods of diagnosing and treating various human cancers and diseases that express KID3.
Type:
Grant
Filed:
September 17, 2004
Date of Patent:
September 7, 2010
Assignee:
MacroGenics, Inc.
Inventors:
Tony W. Liang, Deryk T. Loo, Xiaolin Xu